Common variable immunodeficiency (CVID) is characterized by hypogammaglobulinaemia and recurrent respiratory and gastrointestinal infections [1] . These infections often have a protracted and complicated course, particularly when due to viruses that are antibody-dependent for clearance, such as enteroviruses [2, 3] . Enteroviral disease in CVID can cause high morbidity and mortality [4] . Human parechoviruses (HPeVs) are a recently recognized widely circulating genus within the family of Picornaviridae and are closely related to the enteroviruses [5] . HPeV can cause gastrointestinal and respiratory disease in healthy individuals. Severe symptoms have been reported in rare cases [6] . Information on HPeV infections in CVID patients is scarce, which might be due to the lack of sensitivity of diagnostic tests. Molecular methods for the detection of human parechoviruses, such as reverse transcriptase PCR, have only recently been developed [7] and are routinely used in only a few centres.
Pleconaril inhibits viral replication by binding to a hydrophobic pocket in the viral capsid of Picornaviridae, thereby preventing viral uncoating and viral attachment [8] . The clinical implementation of pleconaril was hampered by inconclusive results of clinical trials [9] [10] [11] . Nonetheless, pleconaril was effective in patients with potential life-threatening enteroviral infections [12] , as well as in other immunocompromised patients [13] . Its effect on the closely related HPeV remains unknown.
We report here on the effect of pleconaril administration to a CVID patient with progressive protein-losing enteropathy (PLE), in whom infection with HPeV was confirmed.
Case report
A 14 year old boy diagnosed with CVID presented in October 2007 at our outpatient clinic with chronic diarrhoea, nausea and abdominal pain. The diagnosis of CVID had been made at the age of 5 years, based on agammaglobulinaemia with normal B-cell numbers, deficient antibody production after antigen and polysaccharide vaccinations, and the exclusion of other immunodeficiency. Numbers of natural killer cells, CD4 + and CD8 + T-cells were normal and T-cell proliferation upon in vitro mitogen or antigen stimulation was undisturbed. The patient subsequently received intravenous immunoglobulin (IVIG) replacement therapy. Immunoglobulin (Ig) G trough levels were maintained at a minimal level of 7 g/l and the patient experienced relatively few infections.
Following the initial presentation, disease progression resulted in severe PLE, causing a weight loss of 19% of the patient's body weight. Physical examination showed /l) and thrombocytopenia (platelet 102×10 9 /l). Antibodies were found against granulocytes (anti-FcR3) and thrombocytes.
Biopsies taken from the oesophagus, antrum, duodenum, distal ileum, colon and sigmoid, all showed lymphocytic infiltration. Immunohistochemistry on these infiltrates revealed a marked increase of CD3 + CD8 -T-cells and a lack of IgA + CD138 + plasma cells. Furthermore, there was duodenal villous atrophy and apoptotic colitis. Repetitive stool samples and gut biopsies remained negative for bacterial and parasitic pathogens. However, RT-PCR in stool samples and biopsies showed both HPeV and norovirus in high viral loads and 'severe PLE secondary to HPeV and norovirus infection in an immunodeficient patient' was diagnosed.
Parenteral nutrition was started to ensure adequate administration of essential nutrients. Furthermore, attempts were made to eradicate the two viruses. As the use of pleconaril was not approved by the licensing authorities for treatment of HPeV, and our patient could not participate in any compassionate use programme, alternative therapies were tried. Dose and frequency of IVIG infusions were increased, aiming to prevent viraemia (IgG trough levels >20 g/l). For optimal local delivery, additional immunoglobulins were administered via a duodenal tube. Both strategies had no effect on the severity of the PLE. As IG preparations contain predominantly IgG, and because antibody-related immunity in the mucous membranes depends mainly on IgA, other sources of IgA were explored. Human breast milk is a source of IgA and lactoferrin, the latter also being a natural antimicrobial agent [14] . Breast milk of a healthy nursing woman was obtained via a voluntary donation programme and tested for pathogenic microorganisms. One litre was administered daily via the duodenal tube and additional lactoferrin was given. Next, a 10-day course of the antiviral agent ribavirin was administered. Despite the above-mentioned strategies, the viral loads of HPeV and norovirus in the stools remained unaltered and clinical symptoms persisted (Figure 1 and 2) .
To confirm our working diagnosis, earlier obtained stool samples of the patient were re-evaluated. Identical strains of the currently active viruses were already present 2 years prior to current presentation; there were comparable levels of viral replication (Figure 1 ) but no clinical symptoms.
The diagnosis was thus altered to 'enteropathy secondary to a perpetuated immune response and triggered by chronic viral replication in an immunodeficient host'. We initiated immunosuppressive therapy (prednisone 1.5 mg/kg), which resulted in significant amelioration of the gastrointestinal symptoms and improvement of laboratory parameters. Prednisone was tapered and tacrolimus was started; however, complete remission was not reached and viral loads remained persistently high. In order to reach further improvement, and to prevent systemic dissemination of HPeV secondary to immunosuppressants, we decided to administer pleconaril. Reassured by appropriate chemical and clinical data in the investigators brochure [15] , the drug was synthesized on request by Sequoia Research Products Ltd, Reading, UK. With the knowledge of the route of synthesis and the possible side products, the raw material was analysed with NMR-HPLC techniques, melting point and infrared spectroscopy; a batch of 200 mg capsules was manufactured. The capsules were analysed with ultraviolet light. The capsules fulfilled the requirements of the 'uniformity of dosage units' monograph 2.9.40 of European Pharmacopoeia.
The bioavailability of pleconaril was tested in a volunteer who took an oral dose of 400 mg. Plasma samples were analysed by a liquid chromatography tandem mass spectrometry method, developed at the pharmacy of the University Medical Center Utrecht. The method was linear between 0.1 mg/l and 15 mg/l with a limit of detection of 0.05 mg/ml. The maximum plasma concentration was 0.51 mg/l.
The patient received 400 mg pleconaril orally three times a day for 7 days. Therapeutic levels (as described for enteroviruses) of pleconaril were reached (Figure 3) . Although pleconaril was well tolerated, it did not result in a decrease of the HPeV viral load or in any further improvement of symptoms.
Discussion
Patients with severely decreased humoral immunity suffer from recurrent gut infections. The association between specific viral infections and severe gastrointestinal pathology in these patients is unclear, although it is recognized that immunity towards several viruses depends heavily on normal antibody production, as well as intact T-cell and natural killer cell functions. Previous reports have described individual cases of chronic viral carrier ship in patients with humoral immunodeficiency [16] . Large surveys have not been performed, as viral culture lacks sensitivity and PCR has often not been implemented in routine practice.
However, the available data suggest that viruses might have an important role in gut pathology in specific immunodeficient patients. There are several hypotheses for the mechanisms that could underlie this relationship. Firstly, persistent viral infections can cause long-standing gut pathology, as the viral infection itself causes extensive mucosal damage. Secondly, the aberrant immune response in immunodeficient patients frequently results in hyperinflammation. It is possible that this hyperinflammation results from the overproduction of proinflammatory cytokines, aimed at directing the (defective) immune system towards the site of infection. Thirdly, we speculate that classical autoimmunity might occur, resulting from either defective immune regulation (as part of CVID) or as the result of abnormal presentation of autoantigens.
HPeV and norovirus infections usually cause mild symptoms in healthy individuals and rarely lead to serious complications. The patient described here had a longstanding infection with both viruses, which were present for at least 2 years before occurrence of the PLE. Over the years, he has been compliant with IVIG therapy and the manufacturer of his IVIG has not changed; however, we can not rule out the possibility that certain batches contain lower levels of antibodies to HPeV. Data on the levels of specific antibodies in IVIG and their level of protectiveness is not yet available. We hypothesize that this chronically active infection enabled the development of autoimmune enteropathy in this patient. The finding of large numbers of T-cells in the entire gastrointestinal tract supports this hypothesis, although we could not confirm whether these T-cells were directed against HPeV. Although seemingly contraindicated, the use of immunosuppressive therapy usually results in marked clinical improvement in immunodeficient patients with symptoms of autoimmune disease.
Eradication of viral infections in agammaglobulinaemic patients is important not only for viral symptom relief, but also for the prevention of immune dysregulation. Persistent infections in immunocompromised hosts might also imply public health issues. Patients with persistent excretion of, for example, norovirus or HPeV pose a permanent risk of outbreaks in their environment, as soon as strict hygiene is not practiced. In the case of persistent poliovirus excretion, chronic carriers might eventually even preclude the successful eradication of this disease [17, 18] .
Unfortunately, effective therapy is often lacking. Several therapeutic regimens aimed at viral eradication were evaluated in this patient, all failing to influence viral replication. Eventually, pleconaril was synthesized and administered, as this drug had been successful in the treatment of enterovirus/ picornavirus infection in earlier reports [12, 13] . Although we were able to synthesize the drug, perform drug purity assays and maintain trough levels within the therapeutic window, we observed no effect on HPeV excretion. This might be due to lack of susceptibility, the concurrent immunosuppressants or the fact that the underlying immunodeficiency precludes viral eradication, irrespective of the antiviral drugs used. Preliminary in vitro data showed that the HPeV strain of our patient was not susceptible to pleconaril (data not shown). Correction of the immunodeficiency, with cellular therapies or by stem cell transplantation, could be an alternative strategy to achieve viral eradication; the improved safety of these strategies might certainly enable their use in this patient category.
For patients with hypogammaglobulinaemia, future studies should include the role of gastrointestinal infections towards enteropathy. As enteropathy is an important complication in CVID [19] , screening for enteropathogenic viruses could be of immense value. Furthermore, there is a great need for improved safety of more definitive methods to correct the underlying immunodeficiencies in these patients.
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